All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 25th Congress of the European Hematology Association (EHA), the MM Hub spoke to Pieter Sonneveld, Erasmus MC, Rotterdam, NL, who discussed the diagnosis and treatment of high-risk MM after EHA 2020.
Around 10–15% of patients diagnosed with MM are classified as high risk and demonstrate poorer responses to treatment. Here, high-risk MM is defined, and Pieter Sonneveld outlines the diagnostic criteria that impact treatment decisions.
How to diagnose and treat high-risk multiple myeloma after EHA 2020
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox